Posted by Michael Wonder on 09 Feb 2022
HIRA mulls therapeutic outcome based benefits for ultra-expensive drugs
9 February 2022 - Pharmaceutical industry officials are paying attention to how the Korean government will manage health insurance benefits for medicines that cure diseases with a single injection but cost millions of dollars.
Recently, the Government said it would review introducing a new reimbursement system exclusively for high priced drugs.
